secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0001193125-25-152016
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences doses first patient in Phase 2 study of TYRA-300 for low-grade, intermediate risk NMIBC
--------------------------------------------------------------------------------

- SURF302 open-label Phase 2 study of TYRA-300 in FGFR3-altered low-grade IR NMIBC; up to 90 participants at US sites.
- Primary endpoint: complete response rate at three months; initial CR data expected first half 2026.
- Patients randomized to 50 mg QD or 60 mg QD; additional dosing cohort may be evaluated.
- TYRA-300 also being studied in pediatric achondroplasia in BEACH301 Phase 2; first child dosing expected H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000119312525152016/0001193125-25-152016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000119312525152016/d11524d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-152016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer